# GenBody COVID-19 Antigen Rapid Test Kit Anterior Nasal Swab 

For Point of Care

Rapid detection of SARS-CoV-2 will play a key role in the global spread of the virus.

Affordable and sensitive test that does not require an additional reader, with a processing time of 15-20 minutes.

For use under an Emergency Use Authorization (EUA) Only
For in vitro diagnostic use only
For professional use only

## $\mathrm{R}_{\mathrm{X}}$ only



## Features

- Detects SARS-CoV-2 nucleocapsid protein antigen
- Rapid results in 15-20 minutes
- Anterior nasal swab specimen collection
- Identifies acute infection with a $92.31 \%$ sensitivity and $99.04 \%$ specificity
- For use in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation.
- The confirmed LoD for the GenBody COVID-19 Ag is $1.11 \times 10 \mathrm{TCID} 50 / \mathrm{mL}$.


## Our Competitive Advantage

- Large manufacturing capacity and immediately available for distribution
- Global sales and regulatory approval throughout Europe, Asia and South America
- Selected by NIH for the Rapid Acceleration of Diagnostics program, for the US production of the GenBody COVID-19 Ag test.
- Made in the USA (Q4 2021) and South Korea
- The GenBody COVID-19 Ag test detects the Sars-CoV-2 variants.

The GenBody COVID-19 Ag is an immunochromatographic rapid diagnostic test (RDT) intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct nasopharyngeal swab (NP) or anterior nasal (AN) specimens from individuals who are suspected of COVID-19 by their healthcare provider within the first six days of symptom onset. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance or Certificate of Accreditation.

## Procedure

## 01

Add the Extraction solution to the Fill Line indicated on the Extraction Tube


## 02

Collect anterior nasal swab specimen.


## 03

Insert the collected specimen swab into the Extraction Solution. Mix by squeezing the tube and simultaneously rotating the swab 8~10 times. Place the Dropper Tip


## Result Interpretation

Read the results between 15-20 minutes.
Do not read after 20 minutes.


## Positive

SARS-CoV-2 antigen present does not rule out co-infection with other pathogens. The color intensity in the test region will vary depending on the amount of SARS-CoV-2 antigen present in the sample. Any faint colored line(s) in the test region(s) should be considered as positive.

## GenBody COVID-19 Ag Kit

## 04

Place test device on a level surface. Add 4 drops of the solution to the sample well.



Negative


Negative test results do not preclude infection and should not be used as the sole basis for treatment or other patient management decisions, including infection control decisions. It is recommended that these results be confirmed by a molecular testing method, if necessary for patient management.

## Invalid



If the Control line does not appear within the designated incubation time (i.e., 15-20 minutes), the result is invalid and the test should be repeated with a new sample.

- 25 Single Use Test Devices Individually Foil-Pouched
- 2 Bottles of Extraction Solution
- 25 Single Use Extraction Tubes
- 25 Single Use Dropper Tips
- 25 Sterilized anterior nasal swabs

Between 35.6 to 86 degrees Fahrenheit
21 months from the date of manufacture

COVAG025-NU


## GenBody COVID-19 Performance Comparison (Visually Read Tests)

| Company | Product Name | Sensitivity | Specificity | Limit of Detection $\left(\mathrm{TCID}_{50} / \mathrm{mL}\right)$ |
| :---: | :---: | :---: | :---: | :---: |
| GenBody Inc | GenBody COVID-19 Ag | 92.31\% | 99.04\% | $1.11 \times 10^{2}$ |
| Salofa Oy | Sienna-Clarity COVID-19 Antigen Rapid Test Cassette | 87.50\% | 98.90\% | $1.25 \times 10^{3}$ |
| Inbios International | SCoV-2 Ag Detect Rapid Test | 86.67\% | 100.00\% | $6.3 \times 10{ }^{3}$ |
| Access Bio Inc | CareStart COVID-19 <br> Antigen test | 87.18\% | 100.00\% | $8 \times 10^{2}$ |
| Quidel Corp | QuickVue SARS Antigen Test | 96.60\% | 99.30\% | $7.57 \times 10{ }^{3}$ |
| Abbott Diagnostics | BinaxNOW COVID-19 Ag Card | 84.60\% | 98.50\% | 140.6 TCID $_{50}$ per Swab |
| Orasure Technologies | InteliSwab COVID-19 Rapid Test Pro | 84.40\% | 98.00\% | $2.5 \times 10^{2}$ |
| Phase Scientific | INDICAID COVID-19 Rapid Antigen Test | 84.40\% | 96.80\% | 140 TCID $_{50}$ per Swab |

This product has not been FDA cleared or approved, but has been authorized by FDA under an EUA for use by authorized laboratories; This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

## GenBody COVID-19 Ag Packaging Information



Manufactured by GenBody and exclusively distributed in the U.S. by Kwell Laboratories

FDA

